Risk StewardRisk Steward
NOTES ON HEALTH, MONEY & A CHANGING WORLDPERSONAL PERSPECTIVES · MALAYSIA

A JOURNAL OF PERSPECTIVE

A changing world.
A judgement
of your own.

Progress gives us possibilities.
Perspective helps us choose.

Notes on health, money and the future—exploring what is changing, what we may have overlooked, and what it could mean for our lives.

TURN THE PERSPECTIVE

If we can detect more, what should we do differently?
Beh Risk Steward THE PERSON BEHIND THE PERSPECTIVE ↗

In focus

Fresh questions. Considered perspectives.

A NOTE FROM THE EDITOR

“I’m interested in a brighter future.
And the questions that help us prepare for it.”

Hope and preparation belong in the same conversation. This journal makes room for both.

A little more about Risk Steward ↗
Journal / Perspective

Health & Longevity

What If Waiting for an Organ Became a Thing of the Past?

Imagine being told you need a new kidney—and that one could eventually be made available without waiting for a human donor.

That is the future Martine Rothblatt’s United Therapeutics is working towards. It is an ambitious idea, and one I find deeply hopeful.

Conceptual illustration of a researcher examining a kidney-shaped scaffold in a laboratory.
AI-generated editorial illustration of a research concept, not a photograph of an actual replacement organ, research team or trial participants.

More than one way to build an organ

“Cloning our organs” is an intriguing description, but the work takes several forms. One involves genetically modified pigs whose organs are designed to be more compatible with people. Cloning helps reproduce those donor animals; it does not mean copying a patient’s own kidney. [1]

United Therapeutics’ EXPAND trial is already testing kidneys from pigs with 10 gene edits in people with end-stage kidney disease. Researchers are tracking survival, kidney function, quality of life, rejection and infection. The organs remain investigational. [2]

Other teams within the company are exploring organ scaffolds populated with human cells, including 3D-printed lung structures. A June 2026 peer-reviewed study reported expanding human lung cells into the hundreds of billions—an important step towards having enough suitable cells to engineer lung tissue. It was not a demonstration of a replacement lung working inside a person. [3]

More options change the questions

On 20 October, the company announced its third specialised, biosecure organ-production facility. Facilities do not prove that a treatment works, but they show the scale of the ambition: making organ supply something we could build, rather than only wait for. [4]

There is still much to establish, particularly how reliably these organs function over years, how rejection is managed, and whether treatment can become widely affordable.

What draws me to this research is the possibility of more ordinary days: time with family, returning to work, making plans beyond the next hospital appointment. But it also challenges an assumption: that once a treatment exists, it becomes an option for everyone.

I would separate three questions: does it work reliably, who is medically eligible, and what would access involve? Scientific progress can change the first answer before practical access changes for a particular family. That is a reason to follow the evidence and revisit our assumptions as it develops.

I cannot put a date on that future. Still, a world with more treatment options is worth looking forward to. Preparation today can include understanding our existing protection, the cash available during illness and who could help us navigate treatment choices. None of this requires assuming that an experimental treatment will become routine.

If treatment options expand, how much freedom would our present arrangements give us to consider them?

Research reviewed: 5 November 2026. General education and personal commentary. These organ technologies are at different stages of development. CI eligibility depends on the policy’s precise definitions and conditions; a new transplant technique does not automatically qualify.

References

[1] Eisenson et al., Nature Communications (2024): Gene-edited donor pigs and kidney xenotransplantation

[2] NYU Langone: EXPAND human clinical trial

[3] Rochelle et al., Journal of Clinical Investigation (2026): Expanding human lung cells for tissue engineering

[4] United Therapeutics: Third xenograft production facility, 20 October 2026 (company announcement)

A QUESTION TO CARRY FORWARD

Original article ↗